Ocrevus (ocrelizumab)

pCPA File Number: 21003

Negotiation Status:

Concluded with an LOI

Indication(s):

Multiple Sclerosis, Relapsing

Sponsor/Manufacturer:

Hoffmann-La Roche Ltd.

CDA-AMC Project Number:

SR0519-000

pCPA Engagement Letter Issued:

2018-07-19

Negotiation Process Concluded:

2019-02-13